PTGX (Protagonist Therapeutics) Total Equity: $655.47 Mil (As of Mar. 2026)


PTGX Protagonist Therapeutics Inc PTGX
51 GF Score
Price $131.73
GF Value $59.98
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Protagonist Therapeutics Total Equity?

Protagonist Therapeutics PTGX +5.15% 51 Total Equity is $655.47 Mil as of Mar. 2026. GuruFocus rates PTGX with a GF Score™ of 51/100 and a GF Value™ of $59.98 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Protagonist Therapeutics's total equity for the quarter that ended in Mar. 2026 was $655.47 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Protagonist Therapeutics Total Equity Historical Data

* Premium members only.

The historical data trend for Protagonist Therapeutics's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Protagonist Therapeutics Total Equity Chart

Protagonist Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 300.02 215.61 336.68 675.30 614.71

Protagonist Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 689.05 668.02 645.44 614.71 655.47
PTGX
51GF Score
Protagonist Therapeutics Inc PTGX
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Protagonist Therapeutics Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Protagonist Therapeutics's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=668.188-53.481
=614.71

Protagonist Therapeutics's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=697.459-41.986
=655.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $655.47 Mil mean?
Protagonist Therapeutics (PTGX) has a Total Equity of $655.47 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Protagonist Therapeutics and its competitors.
Is Protagonist Therapeutics' Total Equity too high?
Protagonist Therapeutics' current Total Equity is $655.47 Mil. Overall, Protagonist Therapeutics has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Protagonist Therapeutics' Total Equity compare to IMVT and SYRE?
Protagonist Therapeutics' Total Equity of $655.47 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Protagonist Therapeutics and its competitors. Protagonist Therapeutics's current Total Equity is $655.47 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Protagonist Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Protagonist Therapeutics (PTGX) is currently considered Significantly Overvalued. The stock's GF Value™ is $59.98, compared to a current price of $131.73 — trading 119.6% above its estimated fair value. The current Total Equity is $655.47 Mil. Protagonist Therapeutics' overall GF Score™ is 51/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Protagonist Therapeutics (PTGX), the current Total Equity is $655.47 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Protagonist Therapeutics (PTGX) Overvalued in 2026?

Based on GuruFocus' analysis, Protagonist Therapeutics stock appears to be overvalued. The current stock price of $131.73 is trading 119.6% above its estimated GF Value™ of $59.98. GuruFocus considers Protagonist Therapeutics to be Significantly Overvalued.

Key valuation signals for PTGX:

  • Total Equity: $655.47 Mil
  • GF Value™: $59.98 vs. price of $131.73 (119.6% above fair value)
  • GF Score™: 51/100 with 7 warning signs

No single metric tells the full story. See the PTGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Protagonist Therapeutics Business Description

Address 7707 Gateway Boulevard, Suite 140, Newark, CA, USA, 94560
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
51GF Score

Get the complete analysis for PTGX

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$131.73
Price
$59.98
GF Value